Top 5 Systemic Carbonic Anhydrase Inhibitors for Canine Glaucoma in the UK: 2026 Guide
Published on Wednesday, 25 February 2026
Systemic carbonic anhydrase inhibitors (CAIs) represent a critical therapeutic intervention for managing acute and severe canine glaucoma across the United Kingdom. These oral and parenteral medications reduce aqueous humour production to produce rapid intraocular pressure reduction when topical therapy is insufficient or inappropriate. Acetazolamide and methazolamide are the primary agents used by British veterinary ophthalmologists because they deliver predictable pharmacological action and demonstrable efficacy in emergency presentations. UK veterinary practitioners and owners favour systemic CAIs for their established safety profiles, broad availability through both human and veterinary pharmaceutical suppliers, and cost-effectiveness compared with urgent surgery or some advanced topical agents. Prescribing and procurement decisions in the UK are shaped by NICE-aligned prescribing principles, National Health Service and private veterinary supply channels, owner compliance considerations, and the need for regular systemic monitoring. Potential adverse effects such as electrolyte disturbances, metabolic acidosis, and renal function changes mean these agents are typically used short term and under direct clinical supervision. Selection is driven by clinical urgency, product availability in UK supply chains, individual patient tolerability, and local monitoring protocols. This page reviews the five most clinically relevant systemic CAI formulations available to UK veterinarians and owners heading into 2026.
Top Picks Summary
Diamox (Acetazolamide) 250mg Tablets
Diamox has long been the clinical standard for systemic carbonic anhydrase inhibition in veterinary ophthalmology, offering well-characterised pharmacokinetics and broad availability across UK pharmacies — advantages that make it a go-to choice for emergency reduction of intraocular pressure compared with newer or off-label options. Compared with generics it may carry a modest price premium, but its established dosing guidance and supply continuity are valuable for practices and owners managing canine glaucoma in the UK.
Acetazolamide 250mg Generic Tablets (Accord Healthcare)
Accord Healthcare's 250mg acetazolamide tablets lead on accessibility and cost-effectiveness, combining wide regulatory reach and high manufacturing scale that make them a pragmatic choice for routine oral therapy compared with the niche methazolamide tablet and the higher-cost injectable formulation. Their broad UK distribution and lower unit price give clear value for owners managing canine glaucoma, while still providing a reliable oral option versus the parenteral product's advantages for acute care.
Diamox SR (Acetazolamide Sustained Release) 250mg Capsules
Diamox SR uses a sustained-release formulation to smooth peak-trough plasma levels, enabling reduced dosing frequency and potentially improved owner compliance and fewer peak-related adverse events compared with immediate-release tablets. Although it typically commands a premium price relative to generics, the improved pharmacokinetic profile and reduced need for frequent dose adjustments make it an attractive option for chronic canine glaucoma cases in the UK.
Methazolamide 50mg Tablets (Neptazane Generic)
Methazolamide (Neptazane generic) holds a specialist position due to its distinct pharmacokinetic profile and focused clinical indications, often carrying higher per-tablet pricing and margins than bulk acetazolamide generics. Although less widely available and more expensive than Accord's acetazolamide tablets, it can be a technically preferred oral alternative in particular scenarios and avoids the higher logistics and cost overhead associated with injectable formulations.
Acetazolamide 500mg Powder for Injection (Parenteral)
The 500mg parenteral acetazolamide formulation is the market leader for hospital and acute-care settings because it enables rapid, controlled administration and consistent bioavailability, which justifies its premium pricing compared with oral generics. Its sterile manufacturing and cold-chain or aseptic supply requirements increase unit cost and margin, positioning it as a technically superior but more expensive option relative to the lower-cost oral tablets from Accord and the specialized methazolamide tablets.
What the research and clinical guidance say
Scientific literature, clinical guidelines and veterinary ophthalmology practice support the use of systemic CAIs for rapid reduction of intraocular pressure in acute canine glaucoma. Mechanistically, CAIs inhibit carbonic anhydrase in the ciliary epithelium, reducing bicarbonate formation and aqueous humour secretion. Evidence comes from veterinary case series, controlled clinical trials in related species, and extrapolation from human ophthalmology where similar pharmacology and monitoring principles apply. Professional guidance emphasizes short-term use, dose adjustment for renal disease, and active monitoring of electrolytes and acid-base status during treatment.
Mechanism: CAIs reduce aqueous humour production by inhibiting carbonic anhydrase in the ciliary body, producing measurable intraocular pressure (IOP) reduction within hours in many clinical cases.
Efficacy: Multiple veterinary case series and clinician reports document significant IOP decreases with acetazolamide and methazolamide in acute and emergency glaucoma presentations.
Safety: Commonly reported systemic effects include paresthesia, gastrointestinal upset, electrolyte changes (particularly hypokalemia), metabolic acidosis, and altered renal function; monitoring mitigates risk.
Dosing and administration: Oral acetazolamide and methazolamide dosing should be weight-based and adjusted for renal impairment; sustained-release formulations alter dosing frequency and owner compliance considerations.
Guideline alignment: UK prescribing follows veterinary regulatory guidance and best-practice recommendations that prioritize short-term emergency use, client education, and laboratory monitoring.
Practical note: Parenteral acetazolamide formulations are reserved for situations where oral administration is not possible or immediate systemic effect is required.
Frequently Asked Questions
Which systemic CAI tablet suits most UK dogs with glaucoma?
Diamox (Acetazolamide) 250mg Tablets are a go-to systemic carbonic anhydrase inhibitor for dogs, with a proven role in reducing intraocular pressure when topical therapy is insufficient; it’s rated 4/5 and uses typical dosing of 5–10 mg/kg every 12–24 hours.
What dosing interval is listed for Diamox 250mg?
Diamox (Acetazolamide) 250mg Tablets are typically dosed at 5–10 mg/kg every 12–24 hours, with need for regular electrolyte and acid–base monitoring; the product is rated 4/5.
Is Accord Healthcare acetazolamide 250mg better value than Diamox?
Acetazolamide 250mg Generic Tablets (Accord Healthcare) are positioned as the lower-cost generic option and are rated 4.6/5; Diamox is rated 4/5 and is described as a long-standing clinical standard.
Who should avoid systemic acetazolamide tablets in dogs?
Diamox (Acetazolamide) 250mg Tablets are contraindicated in severe renal or hepatic disease, and require electrolyte/acid–base monitoring due to side effects like polyuria, polydipsia and risk of metabolic acidosis; rating is 4/5.
Conclusion
In the UK context, systemic CAIs remain an essential emergency option for canine glaucoma management. The five formulations covered here — Diamox (Acetazolamide) 250mg Tablets, Acetazolamide 250mg Generic Tablets (Accord Healthcare), Diamox SR (Acetazolamide Sustained Release) 250mg Capsules, Methazolamide 50mg Tablets (Neptazane Generic), and Acetazolamide 500mg Powder for Injection (Parenteral) — reflect the product choices most commonly available to UK veterinary teams in 2026. For many clinicians and owners facing an acute rise in intraocular pressure, Diamox (Acetazolamide) 250mg Tablets is often the preferred first-line systemic option because of its long history of use, well-understood dosing, and immediate availability. We hope you found the overview useful; if you need to narrow or broaden your search, use the site search to refine by formulation, availability, dosing guidance, or monitoring requirements.